Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Acq. announced
Appointed director
|
|
Ocuphire Pharma, Inc. (OCUP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/28/2019 |
GN
| Rexahn Announces Move to Nasdaq |
| 05/13/2019 |
GN
| Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results |
| 04/19/2019 |
GN
| Analysis: Positioning to Benefit within Nordic American Tankers, Safeguard Scientifics, Permian Basin Royalty Trust, Coda Octopus Group, Rexahn Pharmaceuticals, and Diversified Restaurant ?? Research Highlights Growth, Revenue, and Consolidated Results |
| 04/16/2019 |
GN
| Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China |
| 04/12/2019 |
GN
| Rexahn Effects 1-for-12 Reverse Stock Split |
| 04/10/2019 |
GN
| Rexahn Announces Reverse Stock Split |
| 03/27/2019 |
GN
| Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting |
| 03/08/2019 |
GN
| Rexahn Pharmaceuticals Reports 2018 Financial Results |
| 03/01/2019 |
GN
| Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors |
| 02/06/2019 |
GN
| Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium |
| 02/04/2019 |
GN
| Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types |
| 01/24/2019 |
GN
| Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings |
| 01/22/2019 |
GN
| Rexahn Announces Proposed Public Offering of Common Stock and Warrants |
| 01/22/2019 |
GN
| Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium |
| 01/14/2019 |
GN
| Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium |
| 12/11/2018 |
GN
| Market Trends Toward New Normal in CME Group, Ambac Financial Group, Erie Indemnity, FuelCell Energy, Hovnanian Enterprises, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings |
| 12/06/2018 |
GN
| Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline |
| 11/05/2018 |
GN
| Rexahn Reports Third Quarter 2018 Financial Results |
| 10/17/2018 |
GN
| Rexahn Announces $7.5 Million Registered Direct Offering |
| 08/21/2018 |
GN
| Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer |
| 08/06/2018 |
GN
| Rexahn Reports Second Quarter 2018 Financial Results |
| 06/14/2018 |
GN
| Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018 |
| 05/03/2018 |
GN
| Analysis: Positioning to Benefit within PTC, Black Hills, Mack-Cali Realty, Milacron, Rexahn Pharmaceuticals, and Sunoco LP — Research Highlights Growth, Revenue, and Consolidated Results |
| 05/03/2018 |
GN
| Analysis: Positioning to Benefit within PTC, Black Hills, Mack-Cali Realty, Milacron, Rexahn Pharmaceuticals, and Sunoco LP — Research Highlights Growth, Revenue, and Consolidated Results |
| 04/26/2018 |
GN
| Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 03/22/2018 |
GN
| Research Report Identifies Westinghouse Air Brake Technologies, National Western Life Group, Impinj, Ingles Markets, RCI Hospitality, and Rexahn Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 03/13/2018 |
GN
| Rexahn Pharmaceuticals to Present at Two Upcoming Conferences |
| 03/12/2018 |
GN
| Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results |
| 02/08/2018 |
GN
| Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma |
| 01/29/2018 |
GN
| Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™) |
| 01/22/2018 |
GN
| Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting |
| 01/18/2018 |
GN
| Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting |
| 12/11/2017 |
GN
| Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium |
| 11/09/2017 |
GN
| Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference |
|
|
|